| 本文已被：浏览 1017次 下载 767次 |
码上扫一扫！ |
| 癫痫患儿丙戊酸剂量校正血药浓度的非遗传变异影响因素分析 |
| 李晶,聂松柳,王法财,蒋俊杰,杨顺银,高原,王利媛,段自皞,沈炳香 |
|
|
| (安徽医科大学附属六安医院,六安市人民医
院,安徽六安 237005) |
|
| 摘要: |
| 目的:探讨影响癫痫患儿丙戊酸剂量校正血药浓度[C/ D,单位(μg / mL) / (g / d)]的影响因素,为癫痫患儿个体化用药提供参考。 方法:回顾性收集我院 2021 年 166 例癫痫患儿丙戊酸血药浓度监测数据及临床资料,考察性别、年龄、体质量、药物剂型及联合用药对丙戊酸 C/ D 的影响。 结果:癫痫患儿丙戊酸的血药浓度为(66. 53± 21. 02) μg / mL,剂量为(0. 53± 0. 23) g / d,C/ D 为(148. 77±82. 91)(μg / mL) / (g / d)。 年龄≤3、>3 ~ 6、>6 ~ 16 岁患儿的丙戊酸 C/ D 分别为(256. 59±122. 62)、(157. 17±45. 86)、(112. 46±49. 68)(μg / mL) / (g / d)(P<0. 05);体质量≤20、>20~40、>40 kg 患儿的丙戊酸 C/ D 分别为(204. 80±97. 24)、(124. 05±42. 84)、(90. 88±36. 00)(μg / mL) / (g / d)(P<0. 05);性别及联合用药对患儿丙戊酸 C/ D 无显著影响。 结论:对于年龄≤3 岁以及体质量≤20 kg 的癫痫患儿,临床医师应注意适当减少丙戊酸给药剂量,以预防因血药浓度过高而导致不良反应的发生。 |
| 关键词: 丙戊酸 剂量校正血药浓度 癫痫 治疗药物监测 影响因素 |
| DOI：10. 13407/ j. cnki. jpp. 1672-108X. 2023. 10. 001 |
|
| 基金项目:安徽医科大学校科研基金资助项目,编号 2022xkj100;安徽高校自然科学研究项目,编号 KJ2021A0342 |
|
| Non-Genetic Variation Influencing Factors of Dose-Adjusted Blood Concentration of Valproic Acid inChildren with Epilepsy |
| Li Jing, Nie Songliu, Wang Facai,Jiang Junjie, Yang Shunyin, Gao Yuan, Wang Liyuan, Duan Zihao, Shen
Bingxiang |
| (Lu’an Hospital of Anhui Medical University, Lu’an People’s Hospital, Anhui Lu’an 237005, China) |
| Abstract: |
| Objective: To explore the factors that influence the dose-adjusted blood concentration of valproic acid (C/ D, (μg / mL) / (g / d)) in children with epilepsy, so as to provide reference for individualized medication in children with epilepsy. Methods: The monitoring data of blood concentration of valproic acid and clinical data of 166 children with epilepsy admitted into our hospital in 2021 were retrospectively collected, and the effects of gender, age, body wight, drug formulation and drug combination on C/ D of valproic acid were investigated. Results: The blood concentration of valproic acid in children with epilepsy was (66. 53±21. 02) μg / mL, the dose was (0. 53±0. 23) g / d, and the C/ D was (148. 77±82. 91)(μg / mL) / (g / d). The C/ D of valproic acid in children ⩽3 years, from >3 to 6 years, >6 to 16 years were respectively (256. 59±122. 62), (157. 17±45. 86) and (112. 46±49. 68) (μg / mL) / (g / d) (P<0. 05). The C/ D of valproic acid in children with body weight ⩽20 kg, > 20 to 40 kg, > 40 kg were respectively ( 204. 80± 97. 24), (124. 05±42. 84) and (90. 88±36. 00)(μg / mL) / (g / d) (P<0. 05). While gender and drug combination had no significant effect on C/ D of valproic acid. Conclusion: For children with epilepsy ⩽3 years and with body weight ⩽20 kg, clinicians should be particularly aware of the need to appropriately reduce the dose of valproic acid, so as to prevent the occurrence of adverse drug reactions
due to high blood concentration. |
| Key words: valproic acid dose-adjusted blood concentration epilepsy therapeutic drug monitoring influencing factors |
